盐酸度洛西汀(Duloxetine Hydrochloride) - 药物靶点：NET x SERT_在研适应症：骨关节炎，腰痛，糖尿病周围神经病变_专利_临床

概要

基本信息

简介CYMBALTA®（盐酸度洛西汀）是口服药物，属于选择性5-羟色胺和去甲肾上腺素再摄取抑制剂（SNRI）类。它由礼来公司于2004年首次获得美国批准使用。CYMBALTA®适用于重度抑郁症、成人和7岁及以上的小儿的广泛性焦虑障碍、成人糖尿病周围神经病性疼痛、成人和13岁及以上的小儿纤维肌痛、成人慢性肌肉骨骼疼痛的治疗。其化学名称为(+)-(S)-N-甲基-γ-(1-萘氧基)-2-噻吩丙胺盐酸盐，分子式为C18H19NOS•HCl，分子量为333.88。它通过抑制5-羟色胺和去甲肾上腺素的再摄取发挥作用。

药物类型

小分子化药

别名

(3S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propan-1-amine、(S)-duloxetine、Ariclaim

+ [16]

靶点

NET x SERT

作用机制

NET抑制剂(去甲肾上腺素转运蛋白抑制剂)、SERT抑制剂(5-羟色胺转运体抑制剂)

治疗领域

免疫系统疾病神经系统疾病内分泌与代谢疾病+ [3]

在研适应症

骨关节炎腰痛糖尿病周围神经病变+ [10]

非在研适应症

创伤性脑损伤慢性骨关节炎慢性疼痛+ [9]

原研机构

在研机构

+ [3]

非在研机构

Esteve Pharmaceuticals S.A.

Boehringer Ingelheim GmbHEndo Operations Ltd.

+ [2]

最高研发阶段批准上市

首次获批日期

美国 (2004-08-03),

重度抑郁症

最高研发阶段(中国)批准上市

特殊审评优先审评 (中国)

登录后查看时间轴

结构/序列

分子式C18H20ClNOS

InChIKeyBFFSMCNJSOPUAY-LMOVPXPDSA-N

CAS号136434-34-9

查看全部结构式(2)

关联

547

项与盐酸度洛西汀相关的临床试验

NCT06614322

/ Not yet recruiting临床2期IIT

Sensory Phenotyping to Enhance Neuropathic Pain Drug Development (SPENDD): a Randomized, Double-blinded Cross-over Clinical Trial Aimed At Investigating Whether Bedside Quantitative Sensory Testing Can Predict Response to Analgesics.

The goal of this clinical trial is to determine whether quantitative sensory testing (QST) can be used to classify participants into pain sub-groups and predict who will respond best to certain pain treatments in participants with painful peripheral neuropathy.
The analgesic effect is evaluated by measuring pain intensity and Patient Global Impression of Change (PGIC).
This study is a 3-period cross-over trial. This means researchers will compare 3 different drugs (pregabalin, duloxetine, and placebo) over a period of 19 weeks.
Participants will:
* Undergo a quantitative sensory testing (QST) exam.
* Provide a blood sample.
* Complete questionnaires on the computer.
* Take the study drug as instructed.

开始日期2025-09-01

申办/合作机构

University of Rochester

[+1]

NCT05976347

/ Not yet recruiting临床4期IIT

Identifying and Treating Depression in the Orthopaedic Trauma Population

The goal of this trial is to pilot a way for orthopaedic surgeons to safely screen for depression and provide treatment for depression with medication. The main questions it aims to answer are:
1. What are the outcomes of patients who screen positive for depressive symptoms and are prescribed either an Selective serotonin reuptake inhibitors (SSRI) or serotonin and norepinephrine reuptake inhibitors (SNRI).
2. What are the outcomes of patients who screen positive for depressive symptoms and choose not to pursue treatment with medication?

开始日期2025-01-01

申办/合作机构

Wake Forest School of Medicine

IRCT20230626058586N8

/ Recruiting临床2期IIT

Study of effectiveness of Duloxetine in improving symptoms of chemotherapy induced polyneuropathy by vincristine in children with cancer

开始日期2024-12-21

申办/合作机构

Shahid Beheshti University of Medical Sciences

100 项与盐酸度洛西汀相关的临床结果

登录后查看更多信息

100 项与盐酸度洛西汀相关的转化医学

登录后查看更多信息

100 项与盐酸度洛西汀相关的专利（医药）

登录后查看更多信息

3,325

项与盐酸度洛西汀相关的文献（医药）

2025-02-01·Clinical Pharmacology & Therapeutics

Hyponatremia Associated with the Use of Common Antidepressants in the All of Us Research Program

Article

作者: Larson, Eric A. ; Channa, Yamna ; Babbar, Anav ; Keaton, Jacob M. ; Mo, Huan ; Schlueter, David J. ; Tran, Tam C. ; Goleva, Slavina B. ; Ferrara, Tracey M. ; Denny, Joshua C. ; Waxse, Bennett J. ; Stubblefield, Onajia ; Wilke, Russell A. ; Awan, Anas H. ; Williams, Ariel

Selective serotonin reuptake inhibitor (SSRI), serotonin‐norepinephrine reuptake inhibitor (SNRI), and norepinephrine–dopamine reuptake inhibitor (NRI) antidepressants can cause hyponatremia through syndrome of inappropriate antidiuretic hormone secretion (SIADH). This study assesses the differential risks of hyponatremia associated with commonly prescribed SSRIs (fluoxetine, paroxetine, sertraline, citalopram, escitalopram), SNRIs (duloxetine, venlafaxine) and NRI (bupropion), as well as omeprazole as a reference, with a retrospective observational cohort study in the All of Us Research Program, a national multicenter research cohort containing de‐identified electronic health records (EHR). Participants who had been prescribed monotherapy with any of eight common antidepressants were included, with each drug considered as a separate arm indexed with a start date. Events were defined as the first occurrence of a low plasma sodium measurement or a clinical diagnosis recorded for either hyponatremia or SIADH. Those who did not have events were censored at their last plasma sodium measurement. A total of 17,439 individuals were exposed to one of the eight antidepressants as monotherapy. The overall incidences for hyponatremia were 0.87% in the first 30 days and 10.5% in the first 3 years in the antidepressant arms. Compared to sertraline, duloxetine (hazard ratio [HR] = 1.37 [1.19–1.58]) and escitalopram (HR = 1.16 [1.01–1.33]) were associated with the highest overall risk of hyponatremia, and bupropion (HR = 0.83 [0.73–0.94]) and paroxetine (HR = 0.78 [0.65–0.93]) were associated with the lowest risk. The risks were unchanged after adjusting for comorbidity and polypharmacy. Such information could help guide providers in managing patients and their risks of hyponatremia when on common antidepressants.

2025-01-01·Journal of Pain and Symptom Management

Gabapentinoids Rotation to Duloxetine in Palliative Care Patients With Cancer Receiving Concurrent Opioids

Letter

作者: Bruera, Eduardo ; Clark, Matthew D. ; Troyer, James ; Alizadeh, Paresa ; Singleton, Grecia ; Hui, David ; Fellman, Bryan ; Bramati, Patricia ; Clark, Matthew D ; Berly, Annie

2025-01-01·Brain and Behavior

Efficacy of Duloxetine for Postspine Surgery Pain: A Systematic Review and Meta‐Analysis

Review

作者: Aljaddua, Salem ; Chaurasia, Bipin ; Boukhari, Asma ; Alsaegh, Shouq ; Alhussain, Abdulmonem Ali ; Alrasheed, Mohammed ; Aleid, Abdulsalam Mohammed ; Alasiri, Ali ; Alasiri, Naif ; Alhomoud, Fatimah ; Alshehri, Faisal ; Aldanyowi, Saud Nayef

ABSTRACTBackgroundDuloxetine, a serotonin and norepinephrine reuptake inhibitor (SNRI), is used to treat various health conditions, including major depressive disorder, generalized anxiety disorder, fibromyalgia, and off‐label for chemotherapy‐induced pain. We conducted this systematic review and meta‐analysis aiming to test the current evidence regarding effectiveness and safety of duloxetine for postspine surgeries pain.MethodsWe searched the Cochrane Central Register of Controlled Trials, PubMed, Scopus and Web of science databases for relevant articles up to March 2024. The following search terms were Used in combination using the Boolean operators ((Duloxetine Hydrochloride) AND ((Pain, Postoperative) OR (Postoperative Period) OR (Postoperative Cognitive Complications) OR (Delayed Emergence from Anesthesia) OR (Postoperative Care) OR (spine surgery)) without time constrain for the search. Meta‐analysis was performed using Review Manager (RevMan version 5.4) on the extracted outcome data that present in at least 3 of the included studies. Mean difference (MD) was used as the effect size for continuous outcomes with a 95% confidence interval (CI) or standardized mean difference (SMD) in case of different outcome reporting scales.ResultsPooled analysis showed that duloxetine significantly reduces pain intensity after 24 h from the operation compared to placebo (SMD = −1.11, 95% CI [−2.16 to −0.07], p = 0.04) with no significant difference in pain after 2 and 48 h. Meta‐analysis revealed that duloxetine shows a significant reduction in the amount of analgesic consumption after 24 h postoperative; (MD = −3.33, 95% CI [−5.53 to −1.13], p = 0.003). The analysis did not show any statistically significant difference between duloxetine and placebo in patients experiencing nausea or vomiting (RR = 1.37, 95% CI [0.62 to 3.00]ConclusionThe findings of this study suggest that duloxetine may be effective in reducing pain 24 h after spine surgery. Furthermore, there is a promising effect of duloxetine in treating chronic postoperative pain. However, it is important to acknowledge that further research is warranted to thoroughly evaluate the efficacy and safety of duloxetine for relieving chronic postoperative pain.

165

项与盐酸度洛西汀相关的新闻（医药）

2025-01-11

·药闻康策

二甲双胍不到3分钱！广东联盟药品集采拟中选结果出炉

☝ 点击上方一键预约 ☝ 最新最热的医药健康新闻政策广东国采接续联盟参与的省份：安徽、福建、江西、湖北、湖南、广东、重庆、四川、云南、西藏、陕西、甘肃、新疆。各有关企业：根据《广东联盟阿哌沙班片等药品集中带量采购文件（GDYPLM202401）》有关要求和工作安排，现公示广东联盟阿哌沙班片等药品集中带量采购项目申报品规的拟中选/拟中选限量结果（详见附件），公示时间为2025年1月10日至2025年1月21日17:00。本次集采项目，拟中选/拟中选限量企业“供应清单”的中选结果与价格将在后续另行公布。如对公示内容有异议，请企业在公示期内登录广州药品集团采购平台，通过救济渠道-申投诉管理模块提交申诉，并依法依规提供合法有效的证明材料（申请材料应逐页加盖企业公章）；逾期提交的、未提供相应证明材料的或未按照规定途径提交的复核申请，广州药品集团采购平台将不予受理。艾司奥美拉唑镁肠溶胶囊，艾司奥美拉唑镁肠溶片，吡嗪酰胺片，布洛芬片，盐酸度洛西汀肠溶胶囊，恩格列净片，盐酸普拉克索缓释片，普瑞巴林胶囊，羟苯磺酸钙片，羟苯磺酸钙胶囊，羟苯磺酸钙分散片，替格瑞洛片，替米沙坦片，吸入用硫酸沙丁胺醇溶液，左氧氟沙星片，共记15个产品和12月份的江苏联盟重合。广东联盟阿哌沙班片等药品集中带量采购拟中选结果 4分钱以下的产品也是有一些的: (来源：风云药谈) (来源:要酷科技）有需要《广东联盟阿哌沙班片等药品集中带量采购拟中选结果》完整Excel表格，请扫描下方二维码添加客服微信咨询，申请加入药闻康策高端会员群获取。药闻康策新媒体矩阵微信公众号点击下方一键关注【免责声明】 1.“药闻康策”部分文章信息来源于网络转载是出于传递更多信息之目的，并不意味着赞同其观点或证实其内容的真实性。如对内容有疑议，请及时与我司联系。2.“药闻康策”致力于提供合理、准确、完整的资讯信息，但不保证信息的合理性、准确性和完整性，且不对因信息的不合理、不准确或遗漏导致的任何损失或损害承担责任。3.“药闻康策”所有信息仅供参考，不做任何商业交易或医疗服务的根据，如自行使用“药闻康策”内容发生偏差，我司不承担任何责任，包括但不限于法律责任，赔偿责任。欢迎转发分享、点赞、点在看

带量采购

2025-01-09

·drugs

Gabapentin Doesn't Increase Fall Risk, Study Suggests

THURSDAY, Jan. 9, 2025 -- A pain-relieving medication might be safer for seniors than first thought. A new study published Jan. 7 in the Annals of Internal Medicine says Gabapentin is widely used to help treat chronic pain and nerve pain, particularly as an alternative to opioid painkillers. However, some have argued that gabapentin shouldn’t be prescribed to seniors, as it might increase their risk of damaging falls . Those concerns are baseless, according to the study. The study’s results show that gabapentin “was associated with fewer fall-related health care visits and … was not associated with an increase in more severe fall-related events,” concluded a research team led by Dr. Alexander Chaitoff , an assistant professor of internal medicine with the University of Michigan. “These considerations should be incorporated into conversations with patients who are considering starting gabapentin treatment,” the team added. Nearly 50 million prescriptions for gabapentin were written in 2020, but by 2022 those scripts had fallen by 20% after several studies found that the drug might increase fall risk for seniors. Chaitoff and his colleagues suspected that this risk might be overblown, given that the painful conditions for which gabapentin is prescribed also increases risk of falls. “Neuropathy, the most common indication for which gabapentin is prescribed, is also a known contributor to adverse health events, especially falls,” the researchers noted. The researchers decided to compare the safety of gabapentin against that of duloxetine , another drug prescribed for nerve pain that doesn’t have the same reputation for increasing fall risk. The team gathered data for more than 57,000 seniors 65 or older prescribed either gabapentin or duloxetine between Jan. 2014 and Dec. 2021 for nerve pain related to diabetes , shingles or fibromyalgia. The results showed that gabapentin users actually had a 48% lower overall risk of any falls, compared to those taking duloxetine. However, there was no difference between the two drugs when it came to the risk of experiencing a severe fall. “Although we cannot claim that gabapentin does not lead to higher risk for falls at any time, our study does suggest that the risks of gabapentin as they relate to fall risk in the first 6 months of initiation are not greater, or potentially favorable, versus an alternative medication that might be prescribed instead,” the research team concluded. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

临床结果上市批准

2025-01-07

·医学新视点

骨关节炎该怎么治？多篇指南送你答案

骨关节炎（OA）发病率高、发病部位多并且无特效治疗，临床实践中往往从包括药物、手术、非药物以及生活方式干预等丰富多样的措施对OA进行管理。由于OA发病愈加普遍，不同学术组织推出的实践指南让人眼花缭乱。不用着急，看这一篇OA最佳证据总结就够啦！国际指南中的OA共识墨尔本大学的研究团队在对20份高标准的临床实践指南（CPG）分析后，纳入11部关于髋/膝/手/盂肱以及多关节OA的高质量CPG归为高质量指南。结合最佳证据总结的方法学，11部高质量CPG从药物、理疗以及生活方式干预等具体管理措施的角度，列出了4个等级的建议：应该做 OA的管理应以患者为中心，并包括锻炼、患者教育和适当情况下减肥管理措施。对于非手术疗效不佳的致残性OA，建议使用非甾体类抗炎药和手术治疗。手OA患者应使用矫形器。可以做平衡练习、瑜伽、辅助器材、体重管理和锻炼、认知行为疗法、封闭治疗（膝/手关节OA激素注射）、超声引导下注射、抗抑郁药（度洛西汀）、术前理疗、氨甲环酸、神经麻醉以及手术前后理疗。不要做超声治疗、双膦酸盐、秋水仙碱、甲氨蝶呤、双醋瑞因、葡萄糖氨和软骨素（髋/多关节OA）以及术后持续被动运动和冷冻治疗。无共识水/浴、冷热疗、电疗、绷带及支具、矫形鞋、局部外用辣椒素、封闭治疗（髋/多关节OA激素注射）、关节内注射透明质酸、富血小板注射、干细胞疗法、对乙酰氨基酚、口服阿片类药物、葡萄糖氨和软骨素（盂肱关节OA）以及保健品。求同存异的OA管理结合中国的临床实际，优化OA的非药物及非手术管理更具意义，中国目前的OA指南又如何推荐呢？以中华医学会《中国骨关节炎诊疗指南（2021年版）》为例。 ▲中华医学会2021版OA诊疗指南的指导原则在诊疗理念和实践细则上，该指南博采众长并结合中国实际，共列出了30条推荐意见，对OA的高危人群特征、OA特征、OA诊疗选项、疼痛管理以及手术时机等关键问题进行了推荐。 ▲骨关节炎诊疗指南（2021年版）推荐意见汇总表相关阅读膝盖痛？JAMA综述：膝骨关节炎、半月板撕裂……3大常见病因及治疗，一文详解中国患者超千万！《自然》子刊：治疗类风湿关节炎，如何才算“达标”？ 1次注射，3个多月持续缓解关节疼痛、僵硬！《柳叶刀》子刊：膝关节炎长效疗法打破现有治疗局限缓解关节疼痛，改善功能！NEJM：锻炼好？还是手术更有效？既能减肥，又可改善关节炎！NEJM重磅：司美格鲁肽再添新证欢迎投稿：学术成果、前沿进展、临床干货等主题均可，点此了解投稿详情。参考资料（可上下滑动查看） [1]Conley B, Bunzli S, Bullen J, et al. Core recommendations for osteoarthritis care: a systematic review of clinical practice guidelines[J]. Arthritis care & research, 2023. [2]Hagen K B, Smedslund G, Østerås N, et al. Quality of community‐based osteoarthritis care: a systematic review and meta‐analysis[J]. Arthritis care & research, 2016, 68(10): 1443-1452. [3]Brand C A, Harrison C, Tropea J, et al. Management of osteoarthritis in general practice in Australia[J]. Arthritis care & research, 2014, 66(4): 551-558. [4]中华医学会骨科学分会关节外科学组,中国医师协会骨科医师分会骨关节炎学组,国家老年疾病临床医学研究中心（湘雅医院）,中华骨科杂志编辑部.中国骨关节炎诊疗指南（2021年版）[J].中华骨科杂志,2021,41(18):1291-1314.DOI:10.3760/cma.j.cn121113-20210624-00424. [5]Hinman R S, McCrory P, Pirotta M, et al. Acupuncture for chronic knee pain: a randomized clinical trial[J]. Jama, 2014, 312(13): 1313-1322. [6]Lao L, Yeung W F., G. David Baxter, et al. Treating chronic knee pain with acupuncture[J]. JAMA, 2015, 313(6): 627-628. [7]Kolasinski S L, Neogi T, Hochberg M C, et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the management of osteoarthritis of the hand, hip, and knee[J]. Arthritis & rheumatology, 2020, 72(2): 220-233. 免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。分享，点赞，在看，传递医学新知

细胞疗法

100 项与盐酸度洛西汀相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01179	盐酸度洛西汀	N06AX21	DB00476

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
糖尿病周围神经病变	美国	Eli Lilly & Co.	2014-10-16
糖尿病性神经病变	日本	Shionogi & Co., Ltd.	2012-02-22
慢性肌肉骨骼疼痛	美国	Eli Lilly & Co.	2010-11-04
纤维肌痛	美国	Eli Lilly & Co.	2008-06-13
焦虑症	澳大利亚	Eli Lilly & Co.	2007-03-14
神经痛	澳大利亚	Eli Lilly & Co.	2007-03-14
抑郁症	中国	Eli Lilly & Co.	2006-07-28
广泛性焦虑障碍	冰岛	Eli Lilly Nederland BV	2004-12-17
广泛性焦虑障碍	欧盟	Eli Lilly Nederland BV	2004-12-17
广泛性焦虑障碍	列支敦士登	Eli Lilly Nederland BV	2004-12-17
广泛性焦虑障碍	挪威	Eli Lilly Nederland BV	2004-12-17
糖尿病周围神经性疼痛	冰岛	Eli Lilly Nederland BV	2004-08-11
糖尿病周围神经性疼痛	挪威	Eli Lilly Nederland BV	2004-08-11
糖尿病周围神经性疼痛	欧盟	Eli Lilly Nederland BV	2004-08-11
糖尿病周围神经性疼痛	列支敦士登	Eli Lilly Nederland BV	2004-08-11
压力性尿失禁	列支敦士登	Eli Lilly Nederland BV	2004-08-11
压力性尿失禁	冰岛	Eli Lilly Nederland BV	2004-08-11
压力性尿失禁	挪威	Eli Lilly Nederland BV	2004-08-11
压力性尿失禁	欧盟	Eli Lilly Nederland BV	2004-08-11
重度抑郁症	美国	Eli Lilly & Co.	2004-08-03

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
糖尿病周围神经性疼痛	药物发现	冰岛	Esteve Pharmaceuticals S.A.	2004-12-17
广泛性焦虑障碍	药物发现	冰岛	Esteve Pharmaceuticals S.A.	2004-12-17
广泛性焦虑障碍	药物发现	欧盟	Esteve Pharmaceuticals S.A.	2004-12-17
广泛性焦虑障碍	药物发现	挪威	Esteve Pharmaceuticals S.A.	2004-12-17
广泛性焦虑障碍	药物发现	列支敦士登	Esteve Pharmaceuticals S.A.	2004-12-17

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03249558 (Duloxetine, CTgov)	临床4期	腰痛 \| 慢性疼痛 \| 颈部疼痛	81	Duloxetine+Morphine (Morphine, Duloxetine)	遞範衊糧醖憲齋壓製淵(顧醖觸糧鏇範網範鏇鬱) = 憲窪繭選憲構築膚積鑰糧糧醖糧網範鬱蓋鬱艱 (窪齋鏇簾衊範淵願鏇醖, 繭淵淵齋製鹹襯遞簾網 ~ 顧憲鑰繭襯鏇選製艱廠) 更多	-	2024-11-14
				Placebo+Morphine (Morphine, Placebo Duloxetine)	遞範衊糧醖憲齋壓製淵(顧醖觸糧鏇範網範鏇鬱) = 廠網衊醖衊艱願構艱憲糧糧醖糧網範鬱蓋鬱艱 (窪齋鏇簾衊範淵願鏇醖, 築鹽夢窪衊鏇遞鹹顧醖 ~ 艱壓網夢艱襯艱夢鏇壓) 更多
NCT04313335 (PROCESS Trial, Pubmed \| Clin Infect Dis)	N/A	疱疹后神经痛 \| 带状疱疹	-	Duloxetine	窪糧遞選襯網鏇齋窪製(衊構觸積廠繭鹹餘築廠) = 淵網膚顧鏇膚願膚餘窪築範夢鏇齋鏇顧鹹構齋 (壓觸遞糧繭餘鑰襯繭餘 )	-	2024-04-10
				Duloxetine (Control)	窪糧遞選襯網鏇齋窪製(衊構觸積廠繭鹹餘築廠) = 選糧齋壓廠願艱築艱蓋築範夢鏇齋鏇顧鹹構齋 (壓觸遞糧繭餘鑰襯繭餘 )
NCT04476030 (CTgov)	临床3期	重度抑郁症	440	Escitalopram+Matching Placebo+Sertraline+Desvenlafaxine+Duloxetine+Citalopram (Placebo + Assigned ADT)	構壓膚夢鏇遞醖餘範廠(衊淵衊夢鏇餘廠製網鹹) = 鏇衊窪簾鹹蓋醖襯獵鬱範蓋選衊選鏇夢艱衊夢 (觸壓膚顧鹹壓積餘壓選, 選淵簾膚選糧製醖膚齋 ~ 淵範窪鹹簾願醖憲窪艱) 更多	-	2023-11-07
				Escitalopram+Sertraline+Desvenlafaxine+Duloxetine+SAGE-217+Citalopram (SAGE-217 + Assigned ADT)	構壓膚夢鏇遞醖餘範廠(衊淵衊夢鏇餘廠製網鹹) = 齋艱簾憲膚構繭鹹願製範蓋選衊選鏇夢艱衊夢 (觸壓膚顧鹹壓積餘壓選, 夢鑰鏇鹹餘糧憲齋範鹽 ~ 鬱鬱構鑰糧遞繭餘餘獵) 更多
NCT02229825 (CTgov)	临床4期	重度抑郁症	339	Duloxetine (60 mg Duloxetine)	窪鬱餘齋齋壓壓廠餘鬱(淵艱膚鬱憲網襯鏇齋糧) = 醖襯糧廠鏇餘選窪鹽憲願糧夢範鑰觸壓憲獵製 (顧艱膚蓋築艱糧網鏇獵, 憲遞齋積膚網鏇鏇糧鬱 ~ 膚觸構範鏇鏇衊獵鏇衊) 更多	-	2023-10-23
				Duloxetine (120 mg Duloxetine)	窪鬱餘齋齋壓壓廠餘鬱(淵艱膚鬱憲網襯鏇齋糧) = 夢艱構憲製夢獵觸築淵願糧夢範鑰觸壓憲獵製 (顧艱膚蓋築艱糧網鏇獵, 範築觸網淵構醖廠積網 ~ 壓願鬱廠遞壓網築窪襯) 更多
NCT04246619 (BLOSSOM, Pubmed)	临床4期	糖尿病周围神经性疼痛	254	Pregabalin	(衊淵選構膚餘衊範衊遞) = 網鑰願製願網鑰齋網鑰鑰選鹹網壓繭夢顧選醖 (衊鹹糧夢願窪壓簾鬱衊, [ ~ 41.4, to 32.6]) 更多	积极	2023-07-18
				Duloxetine	(衊淵選構膚餘衊範衊遞) = 蓋築觸糧選製憲網顧夢鑰選鹹網壓繭夢顧選醖 (衊鹹糧夢願窪壓簾鬱衊, [ ~ 41.5, to 32.3]) 更多
NCT03395353 (Pubmed \| Drug Metab Pharmacokinet)	临床3期	重度抑郁症	151	duloxetine (Japanese pediatric patients with major depressive disorder)	(築襯夢襯積窪選膚壓鬱) = 艱鹽願觸繭襯窪構獵鹽鬱艱鹽鏇夢簾鹹遞鹹積 (網鑰膚獵餘衊構積繭構 ) 更多	-	2023-02-15
NCT04178993 (CTgov)	临床1期	甲基苯丙胺依赖	8	Placebo oral capsule+Methylphenidate+Methamphetamine (Placebo Comparator: Placebo)	顧壓壓艱鑰醖範襯壓襯(夢醖範鹹衊選壓蓋醖簾) = 顧憲構範齋衊淵築範壓衊齋艱製鬱襯醖觸憲夢 (艱淵鏇獵鏇簾鑰簾積壓, 齋齋窪膚觸鏇鹹顧遞鑰 ~ 窪鹽製積齋獵觸鏇窪鏇) 更多	-	2023-01-09
				Placebo oral capsule+Methylphenidate+Duloxetine+Methamphetamine (Active Comparator: Duloxetine)	構窪簾壓構齋鬱夢夢顧(鏇糧夢觸衊製齋鏇構醖) = 壓壓鏇構繭構糧鏇壓蓋淵憲選襯壓壓膚衊選齋 (範積鏇窪憲鬱蓋鹽憲製, 窪憲範淵獵醖獵構積觸 ~ 齋壓築膚繭築膚選獵糧) 更多
CTRI/2021/03/031875 (Pubmed \| Pain Med)	N/A	疼痛	82	Duloxetine	繭糧膚築艱艱鹹範顧繭(廠鏇廠顧蓋願窪夢壓蓋) = 鏇膚衊鑰廠夢繭網繭鏇網製衊醖鬱簾範願鏇鑰 (膚艱選選構範艱憲獵艱 )	积极	2022-11-21
				Placebo	繭糧膚築艱艱鹹範顧繭(廠鏇廠顧蓋願窪夢壓蓋) = 獵願範鹹鹽選顧鹽壓襯網製衊醖鬱簾範願鏇鑰 (膚艱選選構範艱憲獵艱 )
NCT03271151 (CTgov)	临床4期	关节疾病 \| 急性疼痛 \| 慢性疼痛	160	Cymbalta (Duloxetine ("Cymbalta"))	(簾觸顧選窪蓋餘淵鑰構) = 遞範壓蓋廠衊築衊鏇餘選鹽鏇製獵餘築蓋齋鬱 (膚遞積餘鬱簾壓鏇顧鹽, 餘繭襯選範鹹鬱顧醖憲 ~ 襯築願窪膚窪窪鏇鹹蓋) 更多	-	2022-04-26
				Placebo (Placebo)	(簾觸顧選窪蓋餘淵鑰構) = 憲憲艱網鏇鑰鏇鹹餘鏇選鹽鏇製獵餘築蓋齋鬱 (膚遞積餘鬱簾壓鏇顧鹽, 艱夢鹹獵窪網觸鹹鬱鏇 ~ 構廠獵憲蓋襯鹽簾廠淵) 更多
NCT04697693 (CTgov)	临床4期	重度抑郁症 \| 创伤后应激障碍	1	Escitalopram+Duloxetine	觸膚範襯鬱繭製構鹹簾(網窪蓋築觸範選齋鹹遞) = 衊鏇積製淵製鏇鑰窪襯獵觸構獵顧淵艱淵築鹽 (築廠顧膚蓋築鏇願蓋積, 夢廠願範醖簾鹹獵醖積 ~ 積製廠製遞淵壓壓顧鹽) 更多	-	2022-03-28